ArticleMediterranean journal of rheumatology2026
Patients' Journey and Burden of Disease Among Patients with Psoriatic Arthritis in Greece: A Cross-Sectional Survey.
Article in Mediterranean journal of rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective/Aim: This study aims to explore the patients' journey from symptom onset to diagnosis and treatment and evaluate the humanistic and economic burden of Psoriatic Arthritis (PsA) in Greece. Methods: A cross-sectional online survey was conducted with patients with PsA over 18 years old, members of the Greek patients' association "Reumazin". Data were collected through a structured questionnaire covering socio-demographics, medical history, patients' journey, health-related quality of life (HRQoL) using the Psoriatic Arthritis Quality of Life (PsAQoL) questionnaire, work productivity impairment, treatments, healthcare utilisation, and expenditures over the past 12 months. The economic burden included out-of-pocket expenses and indirect cost. Results: A total of 148 patients with PsA participated, (70% female, median age 56 years). Median times from symptoms onset to rheumatologist visit, diagnosis, and treatment initiation were 11.5, 12.8, and 15.3 months, respectively. Most common initial symptoms were skin rash/psoriasis (77%) and joint pain (45%). Initial specialists visited included dermatologists (42%) and orthopaedics (21%), with 47% of patients initially misdiagnosed. The median PsAQoL score was 9.0 (Q1: 4.0, Q3: 13.0). Among employed participants (47%), median overall work impairment was 30%, and activity impairment was 40%. Mean annual out-of-pocket expenses were €609 (95% CI: €535 - €704), driven by treatment costs (70%). Indirect cost was €3,723 (95% CI: €2,906 - €4,859) with presenteeism accounting for 82%. Conclusion: This study highlights diagnostic delays and the humanistic and economic burdens of PsA in Greece, providing insights into unmet needs to support healthcare providers and policymakers in improving patient care and resource allocation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.